Features | Partner Sites | Information | LinkXpress
Sign In
ElsMed
Ampronix
Schiller

MRI Guidance Used in Brain Cancer Drug Injection Procedure

By Medimaging International staff writers
Posted on 19 Aug 2013
Image: Using MRI navigation, Dr. Chen injects an investigational gene therapy directly into a brain tumor (Photo courtesy of University of California, San Diego Health Sciences).
Image: Using MRI navigation, Dr. Chen injects an investigational gene therapy directly into a brain tumor (Photo courtesy of University of California, San Diego Health Sciences).
Image: The ClearPoint SmartFrame device is a single-use, disposable trajectory frame that is MRI-compatible and enables the MRI-guided alignment and insertion of devices used during ClearPoint procedures (Photo courtesy of MRI Interventions).
Image: The ClearPoint SmartFrame device is a single-use, disposable trajectory frame that is MRI-compatible and enables the MRI-guided alignment and insertion of devices used during ClearPoint procedures (Photo courtesy of MRI Interventions).
Neurosurgeons in California are among the first in the world to utilize real-time magnetic resonance imaging (MRI) guidance for delivery of gene therapy as a potential treatment for brain tumors. Using MRI navigational technology, neurosurgeons can inject Toca 511 (vocimagene amiretrorepvec), a unique investigational gene therapy, directly into a brain tumor. This new application offers a precise way to deliver a therapeutic virus designed to make the tumor vulnerable to cancer-killing drugs.

“With chemotherapy, just about every human cell is exposed to the drug’s potential side-effects. By using the direct injection approach, we believe we can limit the presence of the active drug to just the brain tumor and nowhere else in the body,” said Clark Chen, MD, PhD, chief of stereotactic and radiosurgery and vice-chairman of neurosurgery University of California (UC) San Diego School of Medicine (USA). “With MRI, we can see the tumor light up in real time during drug infusion. The rest of the brain remains unaffected so the risk of the procedure is minimized.”

Toca 511 is a retrovirus engineered to selectively replicate in cancer cells, such as glioblastomas. Toca 511 generates an enzyme that converts an antifungal drug, flucytosine (5-FC), into the anticancer drug 5-fluorouracil (5-FU). After the injection of Toca 511, the patients are treated with an investigational extended-release oral formulation of 5-FC called Toca FC. Cancer cell killing takes place when 5-FC comes into contact with cells infected with Toca 511.

“Inevitably, almost all glioblastoma patients fail currently available therapy. The challenge, in part, is knowing if current drugs are actually penetrating the tumor. This MRI-guided approach will help us deliver this drug into the tumor directly to see if the drug is working,” said Santosh Kesari, MD, PhD, lead investigator and director of neuro-oncology at UC San Diego Moores Cancer Center (USA). “This approach may lead to new treatment options for patients battling several other types of brain cancers.”

Earlier research using gene therapy to treat brain cancer was mostly limited by the failure in delivering the drug into the brain. Under normal conditions, the brain is protected by the blood-brain barrier but this natural defense mechanism also prevents drugs from reaching the cancer cells in patients with brain tumors. Fortunately, 5-FC crosses the blood-brain barrier, and direct injection of Toca 511 into the tumor provides a means to selectively generate chemotherapy within the tumor mass.

To ensure that the adequate amount of Toca 511 is delivered to the region of the tumor, neurosurgeons at UC San Diego Health System utilize state-of-the art MRI guidance, called ClearPoint, to track the delivery and injection processes in real time. The MRI-guided process provides visual validation that the desired amount of drug is delivered into the tumor and provides physicians the ability to make adjustments to optimize the location of drug delivery. The Clearpoint technology was developed by MRI Interventions (Memphis, TN, USA).

Participants in this clinical trial must be 18 years or older; have a single, recurrent Grade 3 or 4 glioma; and have had prior surgery, radiation, and chemotherapy. The MRI-based procedure is minimally invasive and all participants of the study were discharged from the hospital one day after surgery and resumed their normal daily activity.

The phase 1 trial is evaluating the safety and tolerability of Toca 511 in combination with Toca FC (5-FC, extended-release tablets), and is being developed by Tocagen, Inc. (San Diego, CA, USA).

Related Links:

University of California, San Diego Moores Cancer Center
Tocagen
MRI Interventions



Channels

Radiography

view channel

Analysis Tool Shows Proton Therapy Less Expensive Than IMRT for Advanced Head and Neck Cancers

The episodic cost of care using intensity-modulated proton therapy (IMPT) in advanced stage head and neck cancer is less expensive than intensity-modulated radiotherapy (IMRT), according to new findings. The new proof-of-concept study uses a cost analysis tool that can be used to outline the value of competing healthcare... Read more

Nuclear medicine

view channel

PET Imaging Reveals Brain Benefits from Weight Loss After Bariatric Surgery

Imaging studies revealed that weight loss surgery has been found to suppress changes in brain metabolism associated with obesity and improve cognitive function involved in planning, strategizing, and organizing. Therefore, researchers have hypothesized that a specific surgical procedure could reduce risk of Alzheimer’s... Read more

General/Advanced Imaging

view channel
Image: From left, Guy Genin, PhD, John Boyle and Stavros Thomopoulos, PhD, watch as a sample is exposed to stress and force. They have developed algorithms that may lead to the ability to identify weak spots in tendons, muscles and bones (Photo courtesy of Washington University in St. Louis).

Image Analysis Algorithms Devised to Find Weak Spots in Muscles, Tendons, and Bones prone to Tearing, Breaking

Researchers have developed algorithms to detect weak spots in muscles, tendons, and bones predisposed to tearing or breaking. The technology, which needs to be further refined before it is used in patients,... Read more

Imaging IT

view channel

Interactive Dashboard and Visualization Tool Designed for Oncologists

A new tool has been developed to help users of an information system for radiation oncology to analyze data and use metrics to help make more informed decisions. Varian Medical Systems (Palo Alto CA, USA), a developer of cancer treatment technology and informatics software for managing comprehensive cancer clinics, will... Read more

Industry News

view channel

USD 12 Billion Out of Total Spent on Medical Imaging Squandered in the US

The United States wastes close to USD 12 billion on unnecessary medical imaging yearly, according to a new survey of 196 hospital leaders. Smart data company peer60 (American Fork, UT, USA) surveyed 196 healthcare leaders about medical imaging in less than two weeks and found a number of reasons for the squandered resources.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.